VRDN - Company ID 0001590750
The table below shows Viridian Therapeutics, Inc.DE's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $141.00K | $70.57M | $75.00K | $72.00K | $86.00K | $72.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
Viridian Therapeutics, Inc.DE reported annual revenue of $70.85M for fiscal year 2025. That is up 23359.9% from $302.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $3.48M (FY 2016) to $70.85M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $38.68M |
| $24.32M |
| $20.22M |
| $17.10M |
| $14.41M |
| $16.07M |
| Operating income | -$116.17M | -$40.01M | -$106.77M | -$93.87M | -$83.48M | -$72.19M |
| Income tax | - | - | - | - | - | - |
| Net income | -$104.90M | -$34.60M | -$100.73M | -$86.91M | -$76.69M | -$64.99M |
| EPS (diluted) | - | - | - | - | -$1.15 | -$1.02 |